Français Japonais Chinois Allemand Néerlandais Espagnol Portugais


    Lille to lead French bid for EMA

    France selects Lille to lead the country’s bid to provide a post-Brexit home to the European Medicine Agency.

    Aircraft factory of the future in Méaulte

    Stelia Aerospace has invested €70 million in a complete overhaul of its Méaulte production plant, making this site in the Somme area of Hauts-de-France one of Europe’s most modern aircraft factories.

    All news

    OncoLille consortium recognized by France’s National Cancer Institute

    18 Feb 2013 | A region on the move, Health Nutrition

    Leading-edge cancer research in Northern France wins key credential

    OncoLille  - France’s National Cancer Institute - Oscar Lambret - Lille Region

    Like NCI-designated Comprehensive Cancer Centers in the US, France’s SIRIC labs are dedicated to promoting highly specialized, multidisciplinary cancer research, with the ultimate goal of raising the bar for every aspect of cancer research in France.

    In 2012 OncoLille, a research consortium composed of teams at the Lille CHRU university hospital center and the Centre Oscar-Lambret, was named an official SIRIC center—a top honor acknowledging its expertise as an integrated cancer research site.

    At OncoLille, experts from industry and academia work together in a fully integrated consortium that ranges from fundamental research to roll-out of promising drugs, in addition to addressing key issues in life sciences, social sciences and the humanities.

    OncoLille is currently developing an innovative integrated research project with two components critical to modern oncology:

    • “Resistance,” examining the resistance of tumors and their hosts to locoregional therapies
    •  “Dormancy,” tracking tumors that remain dormant for months or even years.

    The program is funded by a five-year €6,650,000 grant from the French National Cancer Institute.

    OncoLille’s fully integrated approach, which combines all areas of cancer research, is unique in collecting information that is critical to adapting therapeutic practices to personalized medicine. Its designation as a SIRIC center should have an impact beyond academia, generating powerful momentum for businesses throughout the region’s oncology sector. 


    Source : press releases from the Lille CHRU and the National Cancer Institute - Eurasanté



    Back to news